Morgan Stanley
TXG icon

Morgan Stanley’s 10x Genomics TXG Stock Holding History

Morgan Stanley’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129M Buy
3,351,911
+695,558
+26% +$18.2M 0.01% 1354
2026
Q1 		$56.4M Sell
2,656,353
-540,540
-17% -$10.8M ﹤0.01% 1982
2025
Q4 		$52.1M Buy
3,196,893
+379,651
+13% +$5.74M ﹤0.01% 2037
2025
Q3 		$32.9M Sell
2,817,242
-669,713
-19% -$8.73M ﹤0.01% 2399
2025
Q2 		$40.4M Buy
3,486,955
+712,864
+26% +$6.5M ﹤0.01% 2122
2025
Q1 		$24.2M Sell
2,774,091
-1,151,180
-29% -$14.5M ﹤0.01% 2500
2024
Q4 		$56.4M Sell
3,925,271
-2,551,036
-39% -$40.3M ﹤0.01% 1731
2024
Q3 		$146M Buy
6,476,307
+702,439
+12% +$14.5M 0.01% 991
2024
Q2 		$112M Buy
5,773,868
+609,361
+12% +$16M 0.01% 1101
2024
Q1 		$194M Buy
5,164,507
+985,092
+24% +$43.3M 0.02% 811
2023
Q4 		$234M Sell
4,179,415
-170,635
-4% -$7.42M 0.02% 703
2023
Q3 		$179M Sell
4,350,050
-1,298,035
-23% -$67.5M 0.02% 745
2023
Q2 		$315M Sell
5,648,085
-4,872,606
-46% -$264M 0.03% 542
2023
Q1 		$587M Buy
10,520,691
+200,995
+2% +$9.39M 0.06% 296
2022
Q4 		$376M Sell
10,319,696
-107,676
-1% -$3.52M 0.04% 433
2022
Q3 		$297M Buy
10,427,372
+1,530,496
+17% +$58.3M 0.04% 441
2022
Q2 		$403M Sell
8,896,876
-404,980
-4% -$21M 0.05% 350
2022
Q1 		$708M Buy
9,301,856
+4,443,059
+91% +$389M 0.1% 209
2021
Q4 		$724M Sell
4,858,797
-1,216,315
-20% -$186M 0.09% 220
2021
Q3 		$884M Buy
6,075,112
+1,747,269
+40% +$300M 0.12% 178
2021
Q2 		$847M Buy
4,327,843
+191,777
+5% +$34.7M 0.11% 182
2021
Q1 		$749M Sell
4,136,066
-2,570,353
-38% -$444M 0.11% 189
2020
Q4 		$950M Sell
6,706,419
-3,000,124
-31% -$435M 0.15% 152
2020
Q3 		$1.21B Buy
9,706,543
+1,485,146
+18% +$156M 0.23% 98
2020
Q2 		$734M Buy
8,221,397
+3,172,819
+63% +$247M 0.16% 140
2020
Q1 		$315M Buy
5,048,578
+3,958,168
+363% +$309M 0.09% 205
2019
Q4 		$83.1M Buy
1,090,410
+633,927
+139% +$38.1M 0.02% 680
2019
Q3 		$23M Buy
+456,483
New +$25.3M 0.01% 1386

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley's TXG Position: Q2 2026 in Review

Morgan Stanley increased its 10x Genomics (TXG) stake by 26% in Q2 2026, buying an estimated $18.2M and bringing the position to 3,351,911 shares worth $129M. The position accounts for 0.01% of the portfolio, ranked #1354.

Morgan Stanley first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.21B in Q3 2020. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Morgan Stanley held 3,351,911 shares of 10x Genomics worth $129M as of Q2 2026.
  • Morgan Stanley bought 695,558 10x Genomics shares in Q2 2026, an estimated $18.2M.
  • 10x Genomics made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1354 holding.
  • Morgan Stanley first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Morgan Stanley's 10x Genomics position peaked at $1.21B in Q3 2020.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.